• Explore /
  • Poster
  • / Risk factors for the continuation of S-1 adjuvant chemotherapy for gastric cancer analyzed from the JCOG1104 phase III trial.

Risk factors for the continuation of S-1 adjuvant chemotherapy for gastric cancer analyzed from the JCOG1104 phase III trial.

Abstract Poster

Authors

null

Takanobu Yamada

Kanagawa Cancer Center, Yokohama, Japan

Takanobu Yamada , Takaki Yoshikawa , Junki Mizusawa , Hitoshi Katai , Akinori Takagane , Shinji Okano , Shin Teshima , Hisayuki Matsushita , Masahiro Goto , Jun Hihara , Yoshiyuki Kawashima , Takeshi Omori , Hisashi Shinohara , Yasuhiro Yuasa , Hiroshi Katayama , Haruhiko Fukuda , Narikazu Boku , Masanori Terashima , Takeshi Sano , Mitsuru Sasako

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Esophageal and Gastric Cancer

Track

Esophageal and Gastric Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

UMIN000007306

Citation

J Clin Oncol 39, 2021 (suppl 3; abstr 196)

DOI

10.1200/JCO.2021.39.3_suppl.196

Abstract #

196

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Gastrointestinal Cancers Symposium

A phase II trial of CapeOX plus nivolumab for early relapsed HER2-negative gastric cancer (JACCRO GC-11: FirSTAR trial).

A phase II trial of CapeOX plus nivolumab for early relapsed HER2-negative gastric cancer (JACCRO GC-11: FirSTAR trial).

First Author: Hiroyuki Arai

First Author: Bang Wool Eom

First Author: Hiroaki Yanagimoto

First Author: Souya Nunobe